Amgen Reports Initiation of Second P-III METEORIC-HF Study of Omecamtiv Mecarbil for Patients with Heart Failure
Shots:
- The P-III METEORIC-HF study involves assessing of omecamtiv mecarbil (25/50 mg- bid) vs PBO in 270 patients in the ratio (2:1) on exercise capacity as determined by cardiopulmonary exercise testing (CPET) with HFrEF at sites throughout the US- Canada and EU
- In 2006- Amgen & Cytokinetics collaborated to develop therapeutics for the activation of cardiac sarcomere for heart failure. The second P-III METEORIC-HF Study is conducted by Cytokinetics in collaboration with Amgen and to be fund by Servier
- Omecamtiv Mecarbil is a cardiac muscle activator evaluated in global P-III GALACTIC-HF study versus PBO for patients with heart failure or have had a hospitalization or admission to an emergency room for heart failure within one year prior to screening
Ref: Amgen | Image: Twitter
Click here to read the full press release
Tags
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com